Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8818437rdf:typepubmed:Citationlld:pubmed
pubmed-article:8818437lifeskim:mentionsumls-concept:C0002598lld:lifeskim
pubmed-article:8818437lifeskim:mentionsumls-concept:C0080203lld:lifeskim
pubmed-article:8818437lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:8818437lifeskim:mentionsumls-concept:C1549081lld:lifeskim
pubmed-article:8818437lifeskim:mentionsumls-concept:C1692758lld:lifeskim
pubmed-article:8818437lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:8818437pubmed:issue7lld:pubmed
pubmed-article:8818437pubmed:dateCreated1996-12-9lld:pubmed
pubmed-article:8818437pubmed:abstractTextParoxysmal atrial fibrillation (PAF) and paroxysmal supraventricular tachycardia (PSVT) leading to hemodynamic compromise are among the most common reasons for admission to the coronary care unit (CCU) and need prompt and efficient therapy. Direct current cardioversion is the therapy of choice, but if found contraindicated or unavailable some antiarrhythmic agents are usually given to restore sinus rhythm. Many of these drugs have obvious limitations, especially in patients with acute myocardial infarction and/or heart failure.lld:pubmed
pubmed-article:8818437pubmed:languageenglld:pubmed
pubmed-article:8818437pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8818437pubmed:citationSubsetIMlld:pubmed
pubmed-article:8818437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8818437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8818437pubmed:statusMEDLINElld:pubmed
pubmed-article:8818437pubmed:monthJullld:pubmed
pubmed-article:8818437pubmed:issn0160-9289lld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:Ceremuzy?skiL...lld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:CybulskaBBlld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:Ku?akowskiPPlld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:MakowskaEElld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:CzepielAAlld:pubmed
pubmed-article:8818437pubmed:authorpubmed-author:Sikora-FracMMlld:pubmed
pubmed-article:8818437pubmed:issnTypePrintlld:pubmed
pubmed-article:8818437pubmed:volume19lld:pubmed
pubmed-article:8818437pubmed:ownerNLMlld:pubmed
pubmed-article:8818437pubmed:authorsCompleteYlld:pubmed
pubmed-article:8818437pubmed:pagination563-6lld:pubmed
pubmed-article:8818437pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:meshHeadingpubmed-meshheading:8818437-...lld:pubmed
pubmed-article:8818437pubmed:year1996lld:pubmed
pubmed-article:8818437pubmed:articleTitleIntravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias.lld:pubmed
pubmed-article:8818437pubmed:affiliationDepartment of Cardiology, Postgraduate Medical School, Warsaw, Poland.lld:pubmed
pubmed-article:8818437pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8818437lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8818437lld:pubmed